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Statins are inhibitors of the HMG-CoA reductase with lipid-lowering properties 
that are routinely prescribed for primary and secondary prevention of 
cardiovascular events (1). In recent years, experimental and observational 
studies have demonstrated that statins have pleiotropic effects over and above 
their anti-lipid mechanism of action, and have been proposed as part of potential 
preventative strategies for decompensation in cirrhosis (1). 
There is a strong experimental rational for such strategies. From a mechanistic 
perspective, simvastatin increases nitric oxide (NO) availability in the cirrhotic 
liver circulation by enhancing the expression and activity of endothelial NO-
synthase and therefore ameliorates portal hypertension, but also prevents 
endothelial dysfunction during endotoxaemia (2). An anti-inflammatory effect is 
achieved through a decreased production of inflammatory cytokines and 
leukocyte migration to the sub-endothelial space. Importantly, mainly mediated 
by upregulation of the nuclear receptor KLF2, statins have anti-fibrotic effects 
due to inhibition of hepatic stellate cell activation by its paracrine interaction 
with endothelial sinusoidal cells (3). 
In their article in Hepatology, Chang and co-authors used the Taiwan National 
Health Insurance database in a nested case-control study to estimate the effect of 
statins on the risk of decompensation, mortality and HCC in patients with 
cirrhosis. Index cases of cirrhosis were identified from a representative sample 
of 1,000,000 people who were followed from 2000 to 2013 (4). The authors used 
propensity score matching and finally selected 675 patients with cirrhosis in 
each of the statin-user and non-statin user group from a potential size of 1172 
statin users. HCV, HBV and alcohol were the included aetiologies of cirrhosis. 
Statin users were defined as cirrhotic patients with more than 28 cumulative 
































































defined daily dose (cDDD) of any statin. Statin users and non-users were well 
matched in baseline characteristics including the Charlson comorbidity index. 
Use of statins was associated with a significantly lower risk of decompensation 
(HR 0.39), mortality (HR 0.46) and HCC development (HR 0.52) in a dose-
response relationship in the overall cirrhotic population, with users with a 
cDDD>365 days having the greatest benefit. When analysed according to the 
aetiology of cirrhosis, statin use was associated with a reduced risk of 
decompensation in HBV and HCV and a trend for lower risk of decompensation 
in ALD, but no change in the risk of mortality or HCC in independent aetiologies 
(likely due to lower number of patients/events in this sub analysis). 
An advantage of this study compared to other population studies is that it 
derives from a well-validated g neral population database, thus significantly 
reducing the risk of selection bias. There are inevitable weaknesses as with such 
retrospective analyses, which include the lack of patients with NASH cirrhosis, 
the absence of laboratory parameters (with ensuing inability to calculate and 
correct for the MELD and Child-Pugh score), a potential lead-time bias for the 
incident HCC cases and the low threshold (cDDD>28) to classify a patient as 
statin user. Nevertheless, the propensity score matching was robust and non-
bleeding varices at baseline was added in the model to account for the presence 
of clinically significant portal hypertension. The dilution of the statin effect in 
individual aetiologies of cirrhosis is most likely due to type II error rather than 
selective effectiveness in viral hepatitis over alcohol-induced cirrhosis.   
This study adds further observational evidence on the potential beneficial effects 
of statins in patients with cirrhosis. In large cohort studies, statin use was 
protective against significant fibrosis in patients with NAFLD (5) and was 
































































associated with approximately 50% lower risk of progression to cirrhosis in 
patients with HCV (6) and HBV (7). In a cohort of 40,512 patients with 
compensated HCV cirrhosis, statin use was associated with a 40% lower risk of 
decompensation and death (8). Statins have also been associated with reduced 
risk for the development of hepatocellular carcinoma in various liver disease 
aetiologies (1). Importantly, these studies suggest that such effects are class 
effects rather than related to a particular statin and apply to all non-cholestatic 
aetiologies of cirrhosis. However, even promising, these studies need 
confirmation by prospective randomized clinical trials (RCTs). 
There have been two proof of concept prospective RCTs on the use of statins for 
cirrhosis so far. In a RCT of 59 patients, simvastatin given for one month 
significantly reduced portal pressure by an average of 8.3% and was associated 
with a marked improvement in liver indocyanine-green clearance, indicating a 
potential for improved liver function (9). Importantly, the effect on portal 
pressure was over and above that of non-selective beta-blockers. In a further 
RCT in 158 patients with decompensated cirrhosis due to previous variceal 
bleeding, addition of simvastatin to standard of care was independently 
associated with a survival benefit (HR=0.55) in those patients with Child Pugh A 
and B cirrhosis (10). The study is an important guidance to further study design; 
although the primary composite endpoint of reduction of rebleeding or death 
was not achieved, simvastatin had a significant effect in all cause mortality, 
mostly due to less bleeding or infection-related deaths, further reinforcing the 
pleiotropic statin effect (10). This is in keeping with data from pre-clinical 
cirrhotic models showing that statins protect from liver failure secondary to 
sepsis and hypovolemic shock (2). In the BLEPS study, statins were no beneficial 
































































in patients with Child-Pugh C cirrhosis (10). Moreover, there were 2 cases of 
statin-induced rhabdomyolysis in Child-Pugh C patients compared to no cases in 
Child Pugh A or B thus raising efficacy and safety concerns in patients with more 
advanced liver disease. Figure 1 shows the potential beneficial effects of statins 
in the evolution of cirrhosis and combines the presented data. 
The above evidence justifies a phase III RCT of statins in patients with cirrhosis. 
Such a trial should only include compensated patients with Child-Pugh A (and 
potentially Child Pugh B7) with the primary endpoint being a composite 
outcome of decompensation or death. Given the fact that most statins are 
inexpensive and generic drugs, public funding would be required. In an era of 
increasingly expensive medications with profound impact on healthcare budgets, 
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Figure 1. Potential impact of statins on the evolution of chronic liver disease. 
Transition from chronic liver disease to compensated cirrhosis is driven by 
fibrogenesis, while progression from compensated to decompensated cirrhosis is 
mainly driven by complications of portal hypertension. Both disease drivers may 
be attenuated or prevented by statins. Statins may also prevent further 
decompensation due to sepsis and to gastrointestinal bleeding, however there is 
an efficacy and safety concern in patients with Child Pugh C. 
HCC: hepatocellular carcinoma; SBP: spontaneous bacterial peritonitis 
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